Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.18
-5.93 (-2.82%)
AAPL  265.96
+1.38 (0.52%)
AMD  196.08
-4.07 (-2.03%)
BAC  51.28
-1.78 (-3.35%)
GOOG  314.11
-0.79 (-0.25%)
META  642.32
-13.34 (-2.03%)
MSFT  385.64
-11.59 (-2.92%)
NVDA  190.84
+1.02 (0.53%)
ORCL  139.08
-9.00 (-6.08%)
TSLA  398.57
-13.25 (-3.22%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.